Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3893489 | 0.98 | LMNA (0.52) | LMNAF2TSHRTDP1TP53 | |
| Toluene SCHEMBL27970215 | 0.91 | TSHR (0.47) | LMNAF2TSHRTDP1TP53 | |
| SCHEMBL11754892 | 0.85 | TSHR (0.50) | TSHRTP53ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1315543 | 0.82 | LMNA (0.58) | LMNAF2TSHRTDP1TP53 | |
| SCHEMBL4818821 | 0.80 | LMNA (0.56) | LMNAF2TSHRTDP1TP53 | |
| SCHEMBL11746011 | 0.79 | LMNA (0.56) | LMNAF2TSHRTDP1TP53 | |
| SCHEMBL20885264 | 0.79 | LMNA (0.61) | LMNAF2TSHRTDP1TP53 | |
| SCHEMBL28380310 | 0.78 | LMNA (0.54) | LMNAF2TSHRTDP1TP53 | |
| SCHEMBL28895613 | 0.78 | LMNA (0.54) | LMNAF2TSHRTDP1TP53 | |
| SCHEMBL2539028 | 0.78 | F2 (0.54) | LMNAF2TSHRTDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158348-A1 | HERBICIDAL CYCLIC AMIDES N-SUBSTITUTED WITH A HALOALKYLSULFONYLANILIDE GROUP | FMC CORPORATION | 2024-05-16 | — | — | US | disclosed |
| EP-4294791-A1 | HERBICIDAL CYCLIC AMIDES N-SUBSTITUTED WITH A HALOALKYLSULFONYLANILIDE GROUP | FMC CORPORATION (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-111377995-B | Preparation method of prednisolone sodium benzoylsulfonate | 天津药业研究院股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2022177892-A1 | HERBICIDAL CYCLIC AMIDES N-SUBSTITUTED WITH A HALOALKYLSULFONYLANILIDE GROUP | FMC CORPORATION (US) | 2022-08-25 | — | — | WO | disclosed |
| CN-111377995-A | Preparation method of prednisolone sodium benzoylsulfonate | 天津药业研究院有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-111297723-A | Preparation method of collagen and preparation method of application thereof | 宁波赛缪斯生物科技有限公司 | 2020-06-19 | — | — | CN | disclosed |
| CN-107540636-A | A kind of nitogen-contained heterocycle derivant and its application | 成都贝斯凯瑞生物科技有限公司 | 2018-01-05 | — | — | CN | disclosed |
| CN-103910664-B | A kind of antibacterial activity pleuromutilin-sulphone amide derivative and its preparation method and application | 广东温氏大华农生物科技有限公司 | 2016-07-13 | — | — | CN | disclosed |
| CN-101801949-B | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA NV | 2014-09-24 | — | — | CN | disclosed |
| CN-103910664-A | Pleuromutilin-sulfanilamide derivative with antibacterial activity as well as preparation method and application thereof | GUANGDONG DAHUANONG ANIMAL HEALTH PRODUCTS CO LTD | 2014-07-09 | — | — | CN | disclosed |
| EP-1051655-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | Ista Pharmaceuticals, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| CN-1243505-A | Benzamidine derivatives | AJINOMOTO KK (JP) | 2000-02-02 | — | — | CN | disclosed |
| EP-0973392-A1 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1999039238-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | KERATOFORM, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1998038859-A1 | SULFONYL DIVALENT ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| EP-0212741-B1 | A PROCESS FOR THE PREPARATION OF AN AZIDOSULPHONYLBENZOIC ACID | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-12-06 | — | — | EP | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
| US-4666631-A | Process for the preparation of an azidosulphonylbenzoic acid | SHELL OIL COMPANY (US) | 1987-05-19 | — | — | US | disclosed |
| EP-0212741-A1 | A process for the preparation of an azidosulphonylbenzoic acid | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-03-04 | — | — | EP | disclosed |
| US-4001319-A | FROM TRIFLUOROACETYL FLUORIDE AND SULFUR TRIOXIDE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158348-A1 | HERBICIDAL CYCLIC AMIDES N-SUBSTITUTED WITH A HALOALKYLSULFONYLANILIDE GROUP | CBR3, NQO2, CBR1 | LMNA 4264/4885F2 1855/4885TSHR 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.